The use of TILs for cancer treatment is achieved by harvesting CD4+ and CD8+ T lymphocytes from the patient’s tumor, followed by in vitro expansion in a medium supplemented with IL-2 alone or in combination with IL-7, IL-15, and IL-21. This evidence concerns the gene IL2 and neoplasm.